• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    12/11/23 12:30:56 PM ET
    $BMEA
    $CGTX
    $COGT
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BMEA alert in real time by email

    Gainers

    • Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 105.9% to $0.62 during Monday's regular session. The company's market cap stands at $12.8 million.
    • Assure Hldgs (NASDAQ:IONM) stock moved upwards by 32.54% to $0.47. The market value of their outstanding shares is at $3.1 million.
    • Marker Therapeutics (NASDAQ:MRKR) stock moved upwards by 30.51% to $4.19. The company's market cap stands at $37.2 million.
    • MorphoSys (NASDAQ:MOR) stock rose 26.09% to $8.89. The company's market cap stands at $1.2 billion.
    • G1 Therapeutics (NASDAQ:GTHX) stock increased by 20.06% to $3.77. The market value of their outstanding shares is at $195.4 million.
    • Cognition Therapeutics (NASDAQ:CGTX) stock rose 18.67% to $1.97. The company's market cap stands at $60.9 million.

    Losers

    • Cogent Biosciences (NASDAQ:COGT) shares declined by 53.5% to $4.01 during Monday's regular session. The market value of their outstanding shares is at $345.7 million.
    • Altamira Therapeutics (NASDAQ:CYTO) stock decreased by 45.48% to $0.22. The market value of their outstanding shares is at $1.7 million.
    • X4 Pharmaceuticals (NASDAQ:XFOR) stock declined by 29.2% to $0.62. The company's market cap stands at $104.2 million.
    • Jaguar Health (NASDAQ:JAGX) stock decreased by 27.59% to $0.19. The market value of their outstanding shares is at $9.7 million.
    • Biomea Fusion (NASDAQ:BMEA) stock decreased by 25.7% to $12.55. The company's market cap stands at $448.1 million.
    • Vapotherm (NYSE:VAPO) shares decreased by 22.34% to $1.53. The company's market cap stands at $9.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BMEA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMEA
    $CGTX
    $COGT
    $CYTO

    CompanyDatePrice TargetRatingAnalyst
    X4 Pharmaceuticals Inc.
    $XFOR
    3/9/2026$12.00Buy
    Guggenheim
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    X4 Pharmaceuticals Inc.
    $XFOR
    12/5/2025$10.00Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$40.00Hold → Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    Cogent Biosciences Inc.
    $COGT
    10/16/2025$16.00Hold
    Stifel
    Cogent Biosciences Inc.
    $COGT
    9/3/2025$30.00Strong Buy
    Raymond James
    Biomea Fusion Inc.
    $BMEA
    8/28/2025$5.00Buy
    Jefferies
    More analyst ratings

    $BMEA
    $CGTX
    $COGT
    $CYTO
    SEC Filings

    View All

    SEC Form PRE 14A filed by Marker Therapeutics Inc.

    PRE 14A - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/10/26 4:59:15 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jaguar Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    3/9/26 9:05:16 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by X4 Pharmaceuticals Inc.

    SCHEDULE 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    3/6/26 4:24:18 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on X4 Pharmaceuticals with a new price target

    Guggenheim initiated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    3/9/26 9:13:19 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Biomea Fusion with a new price target

    Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

    1/13/26 10:18:10 AM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on X4 Pharmaceuticals with a new price target

    Stifel resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    12/5/25 8:46:35 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Ricciardi Lisa covered exercise/tax liability with 5,850 shares, decreasing direct ownership by 0.34% to 1,706,676 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:17:18 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 1,560 shares, decreasing direct ownership by 0.25% to 617,509 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:16:26 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Caggiano Anthony covered exercise/tax liability with 4,680 shares, decreasing direct ownership by 0.54% to 864,906 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:15:23 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Erdtmann Rainer M bought $42,999 worth of shares (30,000 units at $1.43), increasing direct ownership by 4% to 723,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/15/25 4:15:04 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim CEO Hitchcock Michael J.M. bought $99,180 worth of shares (100,000 units at $0.99), increasing direct ownership by 667% to 115,000 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/4/25 4:15:03 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Erdtmann Rainer M bought $54,552 worth of shares (50,000 units at $1.09), increasing direct ownership by 8% to 693,027 units (SEC Form 4)

    4 - Biomea Fusion, Inc. (0001840439) (Issuer)

    12/2/25 4:15:02 PM ET
    $BMEA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB DIHYDROCHLORIDE has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 4:31:16 PM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for COSELA

    Submission status for G1 THERAPEUTICS INC's drug COSELA (ORIG-1) with active ingredient TRILACICLIB has changed to 'Approval' on 02/12/2021. Application Category: NDA, Application Number: 214200, Application Classification: Type 1 - New Molecular Entity

    2/16/21 11:21:53 AM ET
    $GTHX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

    BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals' website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unme

    3/4/26 7:00:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 24,000 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering i

    3/2/26 4:30:00 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Financials

    Live finance-specific insights

    View All

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

    PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an "unplugged" fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel. Details of Cognition's fireside discussion are as follows: Event: 37th Annual Piper Sandler Healthcare Conference   Date/Time: Wednesday, December 3rd at 4:30p.m. Eastern Time Webcast: https://event.webcasts.com/starthere.jsp?ei=1742473&tp_key=11

    11/20/25 4:01:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMEA
    $CGTX
    $COGT
    $CYTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 7:59:55 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 5:47:15 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 4:05:10 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care